Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | OGG1 | O15527 | 1/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14148139 | 0.81 | NOTUM (0.60) | TP53LMNANOTUMRAB9APKM | |
| SCHEMBL25766220 | 0.77 | TP53 (0.41) | TDP1TP53LMNAOGG1NOTUM | |
| SCHEMBL12559522 | 0.77 | NOTUM (0.64) | TDP1TP53LMNANOTUMALDH1A1 | |
| SCHEMBL21678176 | 0.77 | NOTUM (0.64) | TDP1TP53LMNAOGG1NOTUM | |
| SCHEMBL24011066 | 0.76 | NOTUM (0.63) | TDP1TP53LMNAOGG1NOTUM | |
| SCHEMBL3082421 | 0.76 | NOTUM (0.62) | TDP1TP53LMNAOGG1NOTUM | |
| SCHEMBL30575701 | 0.76 | BRD4 (0.68) | TDP1TP53LMNAOGG1NOTUM | |
| SCHEMBL594384 | 0.76 | NOTUM (0.62) | TDP1TP53LMNAOGG1NOTUM | |
| SCHEMBL24011072 | 0.76 | NOTUM (0.62) | TDP1TP53LMNAOGG1NOTUM | |
| SCHEMBL3585586 | 0.76 | BRD4 (0.68) | TDP1TP53LMNAOGG1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | TDP1 311/4885TP53 1305/4885LMNA 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.